Health
Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial – News-Medical.Net
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled…
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
Dupilumab also rapidly improved lung function…
-
General16 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News23 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
Noosa News16 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General23 hours agoCrowe toasts talkback titan for platforming ‘voiceless’